Enlicitide (MK-0616) Discovery Process: SAR and Preclinical Profiling Data

Enlicitide (MK-0616) is an orally active macrocyclic peptide therapeutic discovered to target PCSK9 for LDL-C reduction. The dataset, shared by Hubert Josien in May 2026, details the modular fragment assembly strategy used to overcome development bottlenecks in a prior lead compound. This approach accelerated the design-make-test-analyze cycle, delivering compounds with low picomolar potency, improved solubility, stability, and pharmacokinetics.

Use Cases

• Analyze structure-activity relationships based on the modular fragment assembly (North/East/South/West/tail) strategy described.
• Model pharmacokinetic properties based on the improved solubility and stability data mentioned for selected compounds.
• Benchmark design-make-test-analyze cycle acceleration methods based on the reported issue-driven synthetic approach.
• Study macrocyclic peptide engineering solutions based on described motifs like the northern lactam staple and RCM-derived cross-link.

Strengths

• Focuses on a specific, clinically progressed compound (Enlicitide/MK-0616) with reported low picomolar potency.
• Describes a concrete methodological innovation: a scalable solution-phase modular fragment assembly to overcome specific development bottlenecks.
• Includes multiple preclinical profiling dimensions mentioned, such as solubility, stability, and pharmacokinetics.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (410.8 KB), indicating limited scope or highly summarized data.

Provenance

Source

Hubert Josien via figshare

Collection Method

Reported from a drug discovery project using modular fragment assembly and SAR.

Freshness

Last updated 2026-05-27 14:40:42; freshness should be verified.